Edison Investment Research - Standard Life UK Small CosTst (SLS) High-conviction portfolio of UK smaller-cap stocks

Report

Edison Investment Research

Mel Jenner

High-conviction portfolio of UK smaller-cap stocks

Standard Life UK Smaller Companies Trust (SLS) aims to generate long-term capital growth from a portfolio of high-quality smaller-cap UK equities. Manager Harry Nimmo follows a long-standing, consistent investment process to construct a relatively concentrated portfolio of c 55 high-conviction holdings. SLS’s NAV total returns are ahead of the benchmark Numis Smaller Companies ex-Investment Companies index over three, five and 10 years and SLS leads the pack versus peers over 10 years. SLS’s annual dividend has compounded at an average annual rate of 23.5% over the last 10 years.

12/01/2017 8 EN

Underlying

Standard Life UK Small CosTst

Standard Life UK Smaller Companies Trust is an investment trust. Co.'s investment objective is to attain long-term capital growth by investment in U.K. quoted smaller companies.

See profile

GB0002959582 London Stock Exchange United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Mel Jenner

Other Reports on these Companies

EQS Group AG

Edison issues update on abrdn UK Smaller Companies Growth Trust (AUSC): Relative performance getting back on track

Edison Investment Research Limited Edison issues update on abrdn UK Smaller Companies Growth Trust (AUSC): Relative performance getting back on track 08-March-2024 / 08:16 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 8 März 2024 Edison issues update on abrdn UK Smaller Companies Growth Trust (AUSC): Relative performance getting back on track abrdn UK Smaller Companies Growth Trust’s (AUSC’s) managers, Abby Glennie and Amanda Yeaman, are looking forward to further improvement in the trust’s relative performance, as investors’ f...

March 8, 2024 March 8, 2024 1 EN

Edison Investment Research

abrdn UK Smaller Companies Growth Trust - Relative performance getting back on track

abrdn UK Smaller Companies Growth Trust’s (AUSC’s) managers, Abby Glennie and Amanda Yeaman, are looking forward to further improvement in the trust’s relative performance, as investors’ focus is now more on company fundamentals rather than macroeconomic developments. The managers are continuing to use the Matrix, a proprietary screening tool, to search for companies exhibiting high-quality, growth and positive momentum features. Despite a difficult period of performance during 2022, when rising interest rates led to a derating of growth stocks, the strategy employed by abrdn’s small-cap team ...

March 8, 2024 March 8, 2024 1 EN

EQS Group AG

Edison issues review on abrdn UK Smaller Companies Growth Trust (AUSC): Performance setback providing good entry point?

Edison Investment Research Limited Edison issues review on abrdn UK Smaller Companies Growth Trust (AUSC): Performance setback providing good entry point? 19-Oct-2023 / 09:06 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 19 October 2023 Edison issues review on abrdn UK Smaller Companies Growth Trust (AUSC): Performance setback providing good entry point? abrdn UK Smaller Companies Growth Trust (AUSC) is managed by Abby Glennie and Amanda Yeaman. The strategy of using the proprietary Matrix screening tool to search for stocks th...

October 19, 2023 October 19, 2023 1 EN

discoverIE Group - FY24 EPS in line; good margin progress

discoverIE anticipates reporting FY24 underlying EPS in line with board expectations. After a period in mid-FY24 of working down inventory, customers appear to be reverting to normal ordering patterns, with Q424 organic revenue growth of 2% y-o-y and 11% q-o-q and a strong pipeline of design wins at year-end. We have revised our forecasts to reflect lower revenue, partly due to a disposal, but maintain our profit forecasts, which results in operating margin expansion in FY24 and FY25.

5h / 57m 5h / 57m 1 EN

Sean Conroy

Sean Conroy

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

April 18, 2024 April 18, 2024 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

April 18, 2024 April 18, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

High-conviction portfolio of UK smaller-cap stocks

Edison issues update on abrdn UK Smaller Companies Growth Trust (AUSC): Relative performance getting back on track

abrdn UK Smaller Companies Growth Trust - Relative performance getting back on track

Edison issues review on abrdn UK Smaller Companies Growth Trust (AUSC): Performance setback providing good entry point?

discoverIE Group - FY24 EPS in line; good margin progress

Ultimovacs - Steadfast commitment to UV1 progression

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe